Benitec develops RNA interference (RNAi)-based therapeutics to treat serious diseases such as AIDS and hepatitis C. RNAi is an exciting new technology that combines target validation and lead drug identification into one step, significantly shortening the drug development cycle when compared to the development of small molecule drugs. Benitec has identified multiple lead drug candidates against hepatitis C virus and expects to be in Phase I trials by the end of 2006.
